Impact of mobility on structure-based drug design for the MMPs

Franklin J. Moy, Pranab K. Chanda, James Chen, Scott Cosmi, Wade Edris, Jeremy I. Levin, Thomas S. Rush, James Wilhelm, Robert Powers

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Structure-based approaches for drug design generally do not incorporate solvent effects and dynamic information to predict inhibitor-binding affinity because of practical limitations. The matrix metalloproteinases (MMPs) have previously been demonstrated to exhibit significant mobility in their active sites. This dynamic characteristic significantly complicates the drug design process based on static structures, which was clearly observed for a class of hydroxamic acids containing a butynyl moiety. Compound 1 was expected to be selective against MMP-1 based on predicted steric clashes between the butynyl P1′ group and the S1′ pocket, but the observation of complex inhibitor dynamics in the NMR structure of MMP-1:1 provides an explanation for the low nanomolar binding to MMP-1.

Original languageEnglish (US)
Pages (from-to)12658-12659
Number of pages2
JournalJournal of the American Chemical Society
Volume124
Issue number43
DOIs
StatePublished - Oct 30 2002

Fingerprint

Matrix Metalloproteinase 1
Drug Design
Matrix Metalloproteinases
Pharmaceutical Preparations
Hydroxamic Acids
Catalytic Domain
Nuclear magnetic resonance
Observation
Acids
Metalloproteases

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Moy, F. J., Chanda, P. K., Chen, J., Cosmi, S., Edris, W., Levin, J. I., ... Powers, R. (2002). Impact of mobility on structure-based drug design for the MMPs. Journal of the American Chemical Society, 124(43), 12658-12659. https://doi.org/10.1021/ja027391x

Impact of mobility on structure-based drug design for the MMPs. / Moy, Franklin J.; Chanda, Pranab K.; Chen, James; Cosmi, Scott; Edris, Wade; Levin, Jeremy I.; Rush, Thomas S.; Wilhelm, James; Powers, Robert.

In: Journal of the American Chemical Society, Vol. 124, No. 43, 30.10.2002, p. 12658-12659.

Research output: Contribution to journalArticle

Moy, FJ, Chanda, PK, Chen, J, Cosmi, S, Edris, W, Levin, JI, Rush, TS, Wilhelm, J & Powers, R 2002, 'Impact of mobility on structure-based drug design for the MMPs', Journal of the American Chemical Society, vol. 124, no. 43, pp. 12658-12659. https://doi.org/10.1021/ja027391x
Moy FJ, Chanda PK, Chen J, Cosmi S, Edris W, Levin JI et al. Impact of mobility on structure-based drug design for the MMPs. Journal of the American Chemical Society. 2002 Oct 30;124(43):12658-12659. https://doi.org/10.1021/ja027391x
Moy, Franklin J. ; Chanda, Pranab K. ; Chen, James ; Cosmi, Scott ; Edris, Wade ; Levin, Jeremy I. ; Rush, Thomas S. ; Wilhelm, James ; Powers, Robert. / Impact of mobility on structure-based drug design for the MMPs. In: Journal of the American Chemical Society. 2002 ; Vol. 124, No. 43. pp. 12658-12659.
@article{fa155500bb604408810c542da7745b73,
title = "Impact of mobility on structure-based drug design for the MMPs",
abstract = "Structure-based approaches for drug design generally do not incorporate solvent effects and dynamic information to predict inhibitor-binding affinity because of practical limitations. The matrix metalloproteinases (MMPs) have previously been demonstrated to exhibit significant mobility in their active sites. This dynamic characteristic significantly complicates the drug design process based on static structures, which was clearly observed for a class of hydroxamic acids containing a butynyl moiety. Compound 1 was expected to be selective against MMP-1 based on predicted steric clashes between the butynyl P1′ group and the S1′ pocket, but the observation of complex inhibitor dynamics in the NMR structure of MMP-1:1 provides an explanation for the low nanomolar binding to MMP-1.",
author = "Moy, {Franklin J.} and Chanda, {Pranab K.} and James Chen and Scott Cosmi and Wade Edris and Levin, {Jeremy I.} and Rush, {Thomas S.} and James Wilhelm and Robert Powers",
year = "2002",
month = "10",
day = "30",
doi = "10.1021/ja027391x",
language = "English (US)",
volume = "124",
pages = "12658--12659",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "43",

}

TY - JOUR

T1 - Impact of mobility on structure-based drug design for the MMPs

AU - Moy, Franklin J.

AU - Chanda, Pranab K.

AU - Chen, James

AU - Cosmi, Scott

AU - Edris, Wade

AU - Levin, Jeremy I.

AU - Rush, Thomas S.

AU - Wilhelm, James

AU - Powers, Robert

PY - 2002/10/30

Y1 - 2002/10/30

N2 - Structure-based approaches for drug design generally do not incorporate solvent effects and dynamic information to predict inhibitor-binding affinity because of practical limitations. The matrix metalloproteinases (MMPs) have previously been demonstrated to exhibit significant mobility in their active sites. This dynamic characteristic significantly complicates the drug design process based on static structures, which was clearly observed for a class of hydroxamic acids containing a butynyl moiety. Compound 1 was expected to be selective against MMP-1 based on predicted steric clashes between the butynyl P1′ group and the S1′ pocket, but the observation of complex inhibitor dynamics in the NMR structure of MMP-1:1 provides an explanation for the low nanomolar binding to MMP-1.

AB - Structure-based approaches for drug design generally do not incorporate solvent effects and dynamic information to predict inhibitor-binding affinity because of practical limitations. The matrix metalloproteinases (MMPs) have previously been demonstrated to exhibit significant mobility in their active sites. This dynamic characteristic significantly complicates the drug design process based on static structures, which was clearly observed for a class of hydroxamic acids containing a butynyl moiety. Compound 1 was expected to be selective against MMP-1 based on predicted steric clashes between the butynyl P1′ group and the S1′ pocket, but the observation of complex inhibitor dynamics in the NMR structure of MMP-1:1 provides an explanation for the low nanomolar binding to MMP-1.

UR - http://www.scopus.com/inward/record.url?scp=0037202174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037202174&partnerID=8YFLogxK

U2 - 10.1021/ja027391x

DO - 10.1021/ja027391x

M3 - Article

VL - 124

SP - 12658

EP - 12659

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 43

ER -